Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Product Spotlight

Sebia

dIFine P30 Processor

Company

Sebia

Name of instrument

dIFine P30 Processor

Contact

Marketing    

Email

info-ai.us@sebia.com 

City, State

Branchburg, NJ

Phone

908-526-3744   

Website

http://www.sebia.com

Type of instrument

immunoassay

List price/First year sold in U.S.

—

Targeted hospital bed size/Targeted test volume

annual: > 5,000

Company manufactures instrument

no

Other models in this family of analyzers

—

No. of units in clinical use in U.S./Outside U.S. (countries)

—

Dimensions (H × W × D)/Instrument footprint

29.1 × 34.6 × 33.1 in./8 sq. ft.

Weight empty/Weight fully loaded

220 lbs./—

No. of different measured assays onboard simultaneously

30 (30 can be run and calibrated at one time)

No. of user-definable (open chemistry) channels

—

Test throughput per hour/Assay run time

assay dependent/—

No. of direct ion-selective electrode channels

—

Detection methods

—

Stat time until completion/specimen throughput for Ion-selective electrode

—

Stat time until completion/specimen throughput for Ion-selective electrode basic metabolic panel

—

Stat time until completion/specimen throughput for Ion-selective electrode complete metabolic panel

—

Typical time delay from ordering stat test until aspiration of sample

—

Fully automated microplate immunoassay system

no

Methodologies supported

fluorescence

Separation methodologies

IFA slide well washing

Stat time until completion of a ß-hCG test

—

Stat time until completion of a cTn test

—

• Typical time delay from test order to aspiration of sample

—

Reagents refrigerated onboard/Reagents ready to use

no/yes

Reagent lot tracking/Reagent inventory

yes/yes

Reagent form/Reagents barcoded

liquid chemistry (open reagent system)/yes

Separate reagent pack for each specimen/for each test run

no/yes

Walkaway capability/Walkaway duration

yes/240 specimens or 30 tests

Design of sample-handling system

rack

Uses washable cuvettes/Uses disposable cuvettes

no/no

Min.–max. sample volume that can be aspirated at one time 

10–1,000 µL

Min. reaction volume/Min. specimen volume/Min. dead volume

—

Dedicated pediatric sample cup

yes

Primary tube sampling

yes

Accommodates most standard tube sizes/Accepts nonstandard tube sizes

yes/no

Pierces caps on primary tubes

no

Protects against probe collision

no

Detects clots/liquid level/short sample

no/yes/yes

Detection or quantitation for hemolysis, icterus, lipemia, clots

hemolysis, icterus, lipemia, clots not available

Dilutes patient samples onboard/Susceptibility to carryover

yes (can be programmed to perform dilutions prior to analysis)/—

Automatic rerun capability

no

Sample volume can be diluted to rerun out-of-linear-range high results

no

Sample volume can be concentrated to rerun out-of-linear-range low results

no

Autocalibration/Multipoint calibration supported

no (calibrants are not stored onboard)/no

Typical calibration frequency for ISE/therapeutic drugs/drugs of abuse/general chemistries/immunoassays

—

Automatic programmable start/Automatic programmable shutdown

no/no

Onboard real-time QC/Onboard software capability to review QC

yes/yes

Supports multiple QC lot numbers per analyte

no

Waste management

automated collection onboard instrument

Sample barcode-reading capability/Autodiscrimination

yes (Interleaved 2 of 5, Codabar, Code 39, Code 128)/no

Lab can control analyzer from remote computer

yes 

Instrument can diagnose its own malfunctions

yes (operator intervention required to order parts)

System malfunctions can be diagnosed via remote monitoring

yes

UPS backup power supply

no

Data-management capability/LIS or EHR systems interfaced

onboard/yes

LIS interface provided/Bidirectional interface capability

no/yes (host query)

Modem servicing provided/Service engineer on-site response time

no/within 24 hrs.

Mean time between failures

— (displays error codes for troubleshooting)

Average scheduled maintenance time by lab personnel

daily: performed automatically; weekly: 5 min.; monthly: 10 min.

Maintenance records kept onboard for user/vendor

no/no

Maintenance training demonstration module onboard

no

Training included with purchase/Avg. time for basic user training

yes (2 training slots)/3 days (at customer site)

Advanced operator training/Extra charge for follow-up or advanced training

yes (at customer site)/no

Warranty provided/Cost of annual service contract (24 h/7 d)

yes (1 year)/—

Distinguishing features (supplied by company)

processes up to 240 samples and 30 IFA slides with a small footprint; fully automated–performs dilution, incubation, washing, mounting, and coverslipping; reliable traceability of samples, reagents, and slides owing to integrated barcode readers

More products
in this guide

Alinity ci-series
ASI Evolution RPR Syphilis Analyzer
DxI 9000 Access Immunoassay Analyzer
Pictus 700 (P700)
Agility Automated ELISA System
AIX1000 Agglutination Instrument
Yumizen C1200
VITROS 3600 Immunodiagnostic System
VITROS 4600 Chemistry System
VITROS XT 7600 Integrated System
cobas pro integrated solutions
IMMULITE 2000 XPi Immunoassay System
Phadia 250 Laboratory System
B⋅R⋅A⋅H⋅M⋅S KRYPTOR GOLD
QUANTA-Lyser 3000